Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  
Facebook    Twitter     Linkedin     RSS     Google+    BLOG    You Tube

Journal of Antivirals & Antiretrovirals

Open Access
ISSN: 1948-5964
French Language  |  English
SCImago Journal & Country Rank

About the Journal

Ralph Welcome Message

Welcome to the Journal of Antivirals and Antiretrovirals (JAA): An open-access, multidisciplinary journal for the discovery and development of antiviral drugs.

I welcome you to a truly interdisciplinary journal which attracts the interest of scientists from various fields such as systems biology, chemistry, virology, and the clinical sciences.
The Journal of Antivirals & Antiretrovirals (JAA) paves the way to discovery and development of antiviral drugs, compounds, and clinical methods to prevent viral infections. Importantly, JAA provides the opportunity to inform researchers, clinicians, and others working in the field of antiviral drugs and therapies. JAA is an internationally recognized journal for scientists involved in basic, applied, and clinical aspects of antiviral and antiretroviral research. It is known that many viruses emerge and re-emerge threatening both animal and human populations. Zoonotic viruses can cause extensive morbidity and mortality; however, preventive vaccines that provide protection are available for only a limited number of viruses.
flyer image Impact Factor: 3.25*
Index Copernicus Value: 4.86
H-Factor: 2
The primary current therapeutic approach against viral diseases is to target viral components that are essential for replication. There are a number of disadvantages targeting viral components including the limited number of druggable viral targets because viruses have a small genome, as well as the rapid development of drug resistance. New drug therapies combine antivirals to increase efficacy and to avoid the development of drug resistant strains. These strategies are effective for viruses such as HIV, but clearly there is a need to expand our drug arsenal to address the wide diversity of viruses. This pathway relies on alternative strategies for drug discovery, such as examining the virus-host interface.
High-throughput RNA interference (RNAi) technology is a platform-enabling technology that allows for rapid searching and validation of biologically relevant target genes in the host. RNAi can be used to silence each and every gene in a host to ask what genes are needed for virus replication. Perhaps the greatest challenge is identify and validate the host genes and pathways they intersect among all the interactions relevant to virus replication. Here, antiviral drugs targeting host genes/factors can be discovered that markedly expand the number of druggable targets that can be temporarily silenced to prevent virus replication. This genome-wide exploration of virus-host interactions allows for a paradigm change in drug discovery because it provides critical host gene/pathway information allowing for drug rescue and repurposing. This systems-based approach to antiviral drug discovery integrates multiple ‘-omics’ approaches because much is learned about host genes co-opted by the virus for metabolomics, and proteins usurped for viral protein trafficking and viral packaging (proteomics), and the like. This information helps to find drugs lacking undesired side effects, and uses a rational approach in drug screening.
As the Editor-in-Chief of Journal of Antivirals & Antiretrovirals, I believe the strength of this open access journal is determined by the quality of manuscripts that it receives, and by the assembly of its editorial board that must encourage contributions from leading investigators. As JAA is an open-access, multidisciplinary journal for the discovery and development of antiviral drugs, it allows for rigorous review and rapid publication without unnecessary delay or expense. I expect JAA to become a venue for top-quality manuscripts and look forward to reading your contributions. Best.
Ralph A Tripp
Department of Infectious Diseases
University of Georgia
Tel. 706-542-1557

Recently published articles

HIV Vertical Transmission: Why is it Still Happening in Brazil?

Vanessa Terezinha Gubert de Matos, Márcia Maria Ferrairo Janini Dal Fabbro, Rivaldo Venancio da Cunha and Ana Lúcia Lyrio de Oliveira

Effect of Nevirapine Administration on Biliary Secretion/its Biochemical Composition in Albino Wistar Rats

Umoren EB, Obembe AO, Odo MO and Osim EE

The Antitumor Activity of Molecular Iodine Complexes with Lithium Halogenides and Bioorganic Ligands when Applied in Combination with Doxorubicin

Gulnara A. Yuldasheva, Georgii M. Zhidomirov, Aleksandr I. Ilin

Microbicides that Can Pop HIV-1

Arangassery Rosemary Bastian

Intestinal Fluid and Glucose Transport in Albino Wistar Rats Following Long Term Administration of Nevirapine

Umoren EB and Obembe AO

Recent Vaccine Development for Human Metapneumovirus

Junping Ren, Thien Phan and Xiaoyong Bao

Therapies for Chronic Hepatitis B: Review of Indications, Outcomes and New Tools for Tailoring Treatments to Patients

Catherine M N Croagh, Sally J Bell and Paul V Desmond

Mechanisms, Consequences, and Treatment of Chronic Inflammation in HIV Disease

R. Keith Reeves

20082014 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version